ADMET considerations for phosphodiesterase-5 inhibitors

Bibliography

• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev 2004;3:711-15
   Google Scholar
• Penzotti JE, Landrum GA, Putta S. Building predictive ADMET models for early decisions in drug discovery. Curr Opin Drug Discov Devel 2004;7:49-60
   PubMed Web of Science ®Google Scholar
• Leonardi R, Alemanni M. The management of erectile dysfunction: innovations and future perspectives. Arch Ital Urol Androl 2011;83(1):60-2
   PubMedGoogle Scholar
• Salari P, Abdollahi M. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012;21(3):261-4
   PubMed Web of Science ®Google Scholar
• Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 2007;17(5):281-8
   PubMed Web of Science ®Google Scholar
• Sung BJ, Hwang KY, Jeon YH, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003;425(6953):98-102
   PubMed Web of Science ®Google Scholar
• Lin CS. Tissue expression, distribution, and regulation of PDE5. Int J Impot Res 2004;1:8-10
   Google Scholar
• Jackson G, Gillies H, Osterloh I. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 2005;59(6):680-91
   PubMed Web of Science ®Google Scholar
• Fekete A, Sasser JM, Baylis C. Chronic vasodilation produces plasma volume expansion and hemodilution in rats: consequences of decreased effective arterial blood volume. Am J Physiol Renal Physiol 2011;300(1):F113-18
   Google Scholar
• Bell AS, Palmer MJ. Novel Phosphodiesterase type 5 modulators: a patent survey (2008 – 2010). Expert Opin Ther Patents 2011;21(10):1631-41
   PubMed Web of Science ®Google Scholar
• Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2010;19(11):1427-37
   PubMed Web of Science ®Google Scholar
• Rahimi R, Ghiasi S, Azimi H, A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine 2010;49(2):123-9
   PubMed Web of Science ®Google Scholar
• Arif SA, Poon H. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther 2011;33(8):993-1004
   PubMed Web of Science ®Google Scholar
• Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009;361:1864-71
   PubMed Web of Science ®Google Scholar
• Domek-Lopacinska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 2008;1216:68-77
   PubMed Web of Science ®Google Scholar
• Reneerkens OA, Rutten K, Steinbusch HW, Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419-43
   PubMed Web of Science ®Google Scholar
• Momtaz S, Abdollahi M. A comprehensive review of biochemical and molecular evidences from animal and human studies on the role of oxidative stress in aging: an epiphenomenon or the cause. Asian J Anim Vet Adv 2012;7(1):1-19
   Web of Science ®Google Scholar
• Khanavi M, Azimi H, Ghiasi S, Specifying human platelet cAMP and cGMP phosphodiesterase inhibitory activity of the plants used in traditional Iranian medicine for the purpose of erectile dysfunction. Int J Pharmacol 2012;8(3):161-8
   Google Scholar
• Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004;16(1):11-14
   Google Scholar
• Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92:9-18
   PubMed Web of Science ®Google Scholar
• Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002;53(Suppl 1):61S-5S
   PubMed Web of Science ®Google Scholar
• Kim TE, Kim BH, Kim JR, Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2009;68(1):43-6
   PubMed Web of Science ®Google Scholar
• Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002;53(1):5-12
   Google Scholar
• Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc 2004;104:11-15
   Google Scholar
• Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005;45:987-1003
   PubMed Web of Science ®Google Scholar
• Walker DK, Ackland MJ, James GC, Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999;29(3):297-310
   PubMed Web of Science ®Google Scholar
• Ku WS, Cho HJ, Yoon IS, Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. Chem Pharm Bull (Tokyo) 2011;59(9):1083-8
   PubMed Web of Science ®Google Scholar
• Steinhorn RH, Kinsella JP, Pierce C, Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009;155(6):841-7
   PubMed Web of Science ®Google Scholar
• Jung SY, Seo YG, Kim GK, Comparison of the solubility and pharmacokinetics of sildenafil salts. Arch Pharm Res 2011;34(3):451-4
   PubMed Web of Science ®Google Scholar
• Toque HA, Teixeira CE, Lorenzetti R, Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008;591(1-3):189-95
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee YS, Bae SH, Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos 2009;30(6):305-17
   PubMed Web of Science ®Google Scholar
• Shin KH, Kim BH, Kim TE, The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther 2009;31(12):3009-20
   PubMed Web of Science ®Google Scholar
• Cho SH, Park H, Kim JH, Effect of sildenafil on gastric emptying in healthy adults. J Gastroenterol Hepatol 2006;21(1 Pt 2):222-6
   PubMed Web of Science ®Google Scholar
• Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther 2011;5:435-43
   PubMed Web of Science ®Google Scholar
• Jung J, Choi S, Cho SH, Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther 2010;32(6):1178-87
   PubMed Web of Science ®Google Scholar
• Silva AC, Toffoletto O, Lucio LA, Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. Arq Bras Cardiol 2010;94(2):150-6; 160-7, 152-8
   PubMedGoogle Scholar
• Jung JY, Kim SK, Kim BS, The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. J Vet Med Sci 2008;70(11):1199-204
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Robey RW, Chen CC, A pharmacodynamic study of the p-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist 2012;17(4):512
   PubMed Web of Science ®Google Scholar
• Di X, Gennings C, Bear HD, Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 2010;124(2):349-60
   PubMed Web of Science ®Google Scholar
• Cheitlin MD, Hutter AM Jr, Brindis RG, ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33(1):273-82
   PubMed Web of Science ®Google Scholar
• CDER/FDA. NDA 021400 levitra (Vardenafil Hydrochloride) tablets - clinical pharmacology/biopharmaceutics review. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; Silver Spring, MD: 2003
   Google Scholar
• CDER/FDA. NDA 021368 cialis (Tadalafil) tablets-clinical pharmacology/biopharmaceutics review. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; Silver Spring, MD: 2003
   Google Scholar
• Mehrotra N, Gupta M, Kovar A, The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007;19(3):253-64
   PubMed Web of Science ®Google Scholar
• Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 2002;53(Suppl 1):45S-52S
   Google Scholar
• Shimada T, Yamazaki H, Mimura M, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-23
   PubMed Web of Science ®Google Scholar
• Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001;51(3):239-48
   PubMed Web of Science ®Google Scholar
• Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 2000;28(4):392-7
   PubMed Web of Science ®Google Scholar
• Wrishko RE, Dingemanse J, Yu A, Pharmacokinetic interaction between tadalafiland bosentan in healthy male subjects. J Clin Pharmacol 2008;48(5):610-18
   PubMed Web of Science ®Google Scholar
• Shon JH, Ku HY, Bae SY, The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics 2011;21(12):820-8
   PubMedGoogle Scholar
• Lee YS, Choi YH, Kim TK, Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats. Xenobiotica 2010;40(2):129-37
   PubMed Web of Science ®Google Scholar
• Lee HS, Park EJ, Ji HY, Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica 2008;38(1):21-33
   PubMed Web of Science ®Google Scholar
• Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003;17(1-4):103-14
   PubMed Web of Science ®Google Scholar
• Ding PR, Tiwari AK, Ohnuma S, The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 2011;6(4):e19329
   Google Scholar
• Medana C, Calza P, Giancotti V, Horse metabolism and the photocatalytic process as a tool to identify metabolic products formed from dopant substances: the case of sildenafil. Drug Test Anal 2011;3(10):724-34
   PubMedGoogle Scholar
• Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4(5):281-97
   PubMedGoogle Scholar
• Al-Ghazawi MA, Tutunji MS, AbuRuz SM. The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur J Clin Pharmacol 2010;66(2):159-63
   PubMed Web of Science ®Google Scholar
• Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother 2007;8(7):965-74
   PubMed Web of Science ®Google Scholar
• Corona G, Razzoli E, Forti G, The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008;31(9):799-808
   PubMedGoogle Scholar
• Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol 2002;53(Suppl 1):31S-6S
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 2002;53(Suppl 1):37S-43S
   Google Scholar
• Available from: http://www.fda.gov/medwatch/safety/2007/Jul_PI/Viracept_PI.pdf
   Google Scholar
• Sekar V, Lefebvre E, De Marez T, Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin Drug Investig 2008;28(8):479-85
   PubMed Web of Science ®Google Scholar
• Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64(1):43-50
   PubMed Web of Science ®Google Scholar
• Stavros F, Kramer WG, Wilkins MR. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol 2010;69(1):23-6
   PubMedGoogle Scholar
• Hesse C, Siedler H, Burhenne J, Fluvoxamine affects sildenafil kinetics and dynamics. J Clin Psychopharmacol 2005;25(6):589-92
   PubMedGoogle Scholar
• Giuliano F, Jackson G, Montorsi F, Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010;64(2):240-55
   PubMed Web of Science ®Google Scholar
• Dworzanski W, Jaskolska A, Szumiło M, Cardiovascular complications of phosphodiesterase-5 inhibitors. Pol Merkur Lekarski 2011;30(176):139-42
   PubMedGoogle Scholar
• Toshiyasu A, Tetsuya I, Katsurou T, Comparative study for the treatment of erectile dysfunction with sildenafil and vardenafil–multi-centric research in Nagano City. Nihon Hinyokika Gakkai Zasshi 2009;100(1):1-6
   PubMedGoogle Scholar
• Taylor J, Baldo OB, Storey A, Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009;103(10):1392-5
   PubMedGoogle Scholar
• Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res 2004;16(1):S28-33
   Google Scholar
• Fraunfelder FT, Fraunfelder FW. Erectile dysfunction agents. In: Drug-induced ocular side effects. 5th edition. Butterworth-Heineman; Boston, MA, 2001. p. 367
   Google Scholar
• Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3(1):12-27
   PubMed Web of Science ®Google Scholar
• Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf 2009;32(1):1-18
   PubMedGoogle Scholar
• Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med 2011;8(10):2894-903
   PubMed Web of Science ®Google Scholar
• Aliferis K, Petropoulos IK, Farpour B, Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica 2012;227(2):85-9
   PubMedGoogle Scholar
• Michelakis E, Tymchak W, Archer S. Sildenafil: from the bench to the bedside. CMAJ 2000;163(9):1171-5
   PubMed Web of Science ®Google Scholar
• Eros D, Szantai C, Kiss R, Structure-activity relationships of PDE-5 inhibitors. Curr Med Chem 2008;15:1570-85
   PubMed Web of Science ®Google Scholar
• Kontaras K, Varnavas V, Kyriakides ZS. Does sildenafil cause myocardial infarction or sudden cardiac death? Am J Cardiovasc Drugs 2008;8(1):1-7
   PubMedGoogle Scholar
• Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: a possible cellular stress etiology. Laryngoscope 2009;119(8):1586-9
   PubMedGoogle Scholar
• Khan AS, Sheikh Z, Khan S, Viagra deafness–sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope 2011;121(5):1049-54
   PubMedGoogle Scholar
• Abbott D, Comby P, Charnel C, Preclinical safety profile of sildenafil. Int J Impot Res 2004;16(6):498-504
   PubMedGoogle Scholar
• Villanueva-Garcia D, Mota-Rojas D, Hernandez-Gonzalez R, A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol 2007;27(3):255-9
   PubMedGoogle Scholar
• Glenn DR, McClure N, Cosby SL, Sildenafil citrate (Viagra) impairs fertilization and early embryo development in mice. Fertil Steril 2009;91(3):893-9
   PubMed Web of Science ®Google Scholar
• Refuerzo JS, Sokol RJ, Aranda JV, Sildenafil citrate and fetal outcome in pregnant rats. Fetal Diagn Ther 2006;21(3):259-63
   PubMedGoogle Scholar
• Abou-Tarboush FM, Abdel-Samad MF, Al-Meteri MH. Developmental toxicity of orally administered sildenafil citrate (Viagra) in SWR/J mice. Saudi J Biol Sci 2011;18:135-9
   PubMed Web of Science ®Google Scholar
• Bingham J, Sudarsanam S, Srinivasan S. Profiling human phosphodiesterase genes and splice isoforms. Biochem Biophys Res Commun 2006;350(1):25-32
   PubMedGoogle Scholar
• Hellstrom WJ, Overstreet JW, Yu A, Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003;170:887-91
   PubMed Web of Science ®Google Scholar
• Pomara G, Morelli G, Canale D, Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. Fertil Steril 2007;88:860-5
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Gittelman M, Jarow J, An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008;53(5):1058-65
   PubMed Web of Science ®Google Scholar
• Dimitriadis F, Giannakis D, Pardalidis N, Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. Asian J Androl 2008;10(1):115-33
   PubMedGoogle Scholar
• Dimitriadis F, Tsambalas S, Tsounapi P, Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU Int 2010;106(8):1181-5
   PubMedGoogle Scholar
• Purvis K, Muirhead GJ, Harness JA. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol 2002;53(Suppl 1):53S-60S
   Google Scholar
• Mostafa T. Oral phosphodiesterase-5 inhibitors and sperm functions. Int J Impot Res 2008;20(6):530-6
   PubMedGoogle Scholar
• Khalaf MA, Abbas MF, El-Fakahany HM. Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats. Andrologia 2012;44(1):370-5
   PubMedGoogle Scholar
• Jarrar BM. Histological alterations in the testicular tissue induced by sildenafil overdoses. Drug Metab Lett 2011;5(2):99-103
   PubMedGoogle Scholar
• Jannini EA, DeRogatis LR, Chung E, How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J Sex Med 2012;9(1):26-33
   PubMed Web of Science ®Google Scholar
• Eardley I, Mirone V, Montorsi F, An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005;96:1323-32
   PubMed Web of Science ®Google Scholar
• Eardley I, Montorsi F, Jackson G, Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 2007;100:122-9
   PubMed Web of Science ®Google Scholar
• Tolra JR, Campana JM, Ciutat LF, Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006;3:901-9
   PubMed Web of Science ®Google Scholar
• Von Keitz A, Rajfer J, Segal S, A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004;45:499-507
   PubMed Web of Science ®Google Scholar
• Govier F, Potempa AJ, Kaufman J, A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23
   PubMed Web of Science ®Google Scholar
• Dean J, Hackett GI, Gentile V, Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61
   PubMed Web of Science ®Google Scholar
• Ozgur BC, Gonenc F, Yazicioglu AH. Sildenafil or vardenafil nonresponders' erectile response to tadalafil. Urol J 2009;6(4):267-71
   PubMed Web of Science ®Google Scholar
• Tsertsvadze A, Fink HA, Yazdi F, Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151:650-61
   PubMed Web of Science ®Google Scholar
• Kumar P, Francis GS, Tang WH. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nat Rev Cardiol 2009;6:349-55
   PubMed Web of Science ®Google Scholar
• De LaVega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opin Investig Drugs 2009;18:23-9
   PubMed Web of Science ®Google Scholar
• Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010;20(1):49-54; Review
   PubMed Web of Science ®Google Scholar
• Zhang X, Zang N, Wei Y, Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab 2012;302(2):243-53
   PubMed Web of Science ®Google Scholar
• Tinsley HN, Gary BD, Keeton AB, Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009;8(12):3331-40
   PubMed Web of Science ®Google Scholar
• Arozarena I, Sanchez-Laorden B, Packer L, Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2009;19:45-57
   Web of Science ®Google Scholar
• Houslay MD. Hard times for oncogenic BRAF-expressing melanoma cells. Cancer Cell 2011;19:3-4
   PubMed Web of Science ®Google Scholar
• Ghiasi S, Ghiasi S, Abdollahi M. A review on the potential benefits of phosphodiesterase inhibitors in various models of toxicities in animals. Asian J Anim Vet Adv 2012;7(3):210-24
   Web of Science ®Google Scholar
• Mohammadi M, Atashpour S, Pourkhalili N, Comparative improvement in function of isolated rat Langerhans islets by various phosphodiesterase 3, 4 and 5 inhibitors. Asian J Anim Vet Adv 2011;6(12):1233-40
   Web of Science ®Google Scholar
• Azadbar M, Ranjbar A, Hosseini-Tabatabaei A, Interaction of phosphodiesterase 5 inhibitor with malathion on rat brain mitochondrial-bound hexokinase activity. Pestic Biochem Physiol 2009;95:121-5
   Web of Science ®Google Scholar
• Ranjbar A, Ghahremani MH, Sharifzadeh M, Protection by pentoxifylline of malathion-induced toxic stress and mitochondrial damage in rat brain. Hum Exp Toxicol 2010;29:851-64
   PubMed Web of Science ®Google Scholar
• Ghafour-Rashidi Z, Dermenaki-Farahani D, Aliahmadi A, Protection by cAMP and cGMP phosphodiesterase inhibitors of diazinon-induced hyperglycemia and oxidative/nitrosative stress in rat Langerhans islets cells: molecular evidence for involvement of non-cholinergic mechanisms. Pestic Biochem Physiol 2007;87:261-70
   Web of Science ®Google Scholar
• Milani E, Nikfar S, Khorasani K, Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 2005;140(2):251-5
   PubMed Web of Science ®Google Scholar
• Abdollahi M, Chan TS, Subrahmanyam V, Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11
   PubMed Web of Science ®Google Scholar
• Hoseini S, Esmaily H, Mohammadirad A, Effects of sildenafil a phosphodiesterase 5 inhibitor on rat liver cell key enzymes of gluconeogenesis and glycogenolysis. Int J Pharmacol 2006;2(3):280-5
   Google Scholar
• Kotera J, Fujishige K, Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodieterase (PDE 5) in rat tissues. J Histochem Cytochem 2000;48:685-93
   PubMed Web of Science ®Google Scholar
• Ghosh R, Sawant O, Ganpathy P, Phosphodiesterase inhibitors: their role and implications. IJPTR 2009;1:1148-60
   Google Scholar
• Schwartz BG, Levine LA, Comstock G, Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 2012;59(1):9-15; Review
   PubMed Web of Science ®Google Scholar
• Kloner RA, Comstock G, Levine LA, Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. Expert Opin Pharmacother 2011;12(15):2297-313; Review
   PubMed Web of Science ®Google Scholar
• Kukreja RC, Salloum FN, Das A, Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol 2011;16(4):30-5
   PubMedGoogle Scholar
• Badri S, Dashti-Khavidaki S, Lessan-Pezeshki M, A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. J Pharm Pharm Sci 2011;14(1):128-37
   PubMed Web of Science ®Google Scholar
• Radfar M, Larijani B, Hadjibabaie M, Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 2005;59:302-6
   PubMed Web of Science ®Google Scholar
• Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother 2010;11(7):1109-22; Review
   PubMed Web of Science ®Google Scholar
• Yadav DK, Khan F, Negi AS. Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity. J Mol Model 2012;18(6):2513-25
   PubMed Web of Science ®Google Scholar